68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Recruiting now · Phase 2

Conditions studied: Neuroendocrine Tumors

In brief

Somatostatin receptor (SSR) imaging is a critical component of clinical care for many patients being investigated for or with confirmed SSR positive tumors. In the past, 111In-octreotide imaging has been used for this purpose but it has been recently supplanted globally by SSR positron emission tomography (PET) imaging due to better image quality and higher diagnostic accuracy. This study will assess the safety and diagnostic effectiveness of 68Ga-HA-DOTATATE produced a the Edmonton Radiopharmaceutical Centre (ERC).

Key facts

Study ID
NCT04888481
Run by
University of Alberta
People needed
600
Starts
2022-02-15
Expected to finish
2028-08-31
Last updated by the study team
2026-05-11

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.